Everstone unit acquires Chemopharm

KUALA LUMPUR: The Everstone Group, via its platform Everlife, has acquired Chemopharm Sdn Bhd, a leading provider of products and services solutions to laboratory, research and medical facilities in Southeast Asia.

In a statement, it said Everlife is in multiple discussions with firms in areas such as lab and diagnostic equipment, patient monitoring and critical care.

The Everlife platform will be led by industry veterans, Troy Bailey and Dr Amit Kakar. Bailey is a seasoned executive with over 20 years of experience in leading medical device businesses in Asia, including GE Healthcare.

Dr Kakar a veteran in the industry for over three decades, has held leadership positions in GE Healthcare and Avenue Capital.

The founder of Cure Capital, Dr Arjun Oberoi, will sit on the Everlife board and work closely with its executive team.

The founder and chief executive officer of Chemopharm, C A Ooi, will continue in his existing role. The rest of Chemopharm’s leadership will also remain integral to the management team.

The Everstone Group has significant experience in the healthcare sector.

Other Everstone investments in healthcare are Rubicon, a pioneering drug delivery technology company in India, as well as OmniActive, a major supplier of naturally sourced ingredients for eye health, weight management and heart health.